A MET-Targeted Variable New Antigen Receptor Theranostic for Non-Small Cell Lung Cancer

This study reports the development and preclinical validation of a shark-derived VNAR-based theranostic agent, vMET1-Fc, which enables high-contrast PET imaging and effective targeted radiotherapy for MET-altered non-small cell lung cancer with a favorable safety profile.

The Gist

The Big Idea: A Shark's Super-Sniffer for Lung Cancer

Imagine you are trying to find a specific, hidden house in a massive, crowded city (the human body). The problem is that the house you are looking for (a cancer cell) looks almost exactly like thousands of other normal houses. Traditional searchlights (standard antibodies) are big, clumsy, and sometimes get stuck on the wrong buildings or can't see the specific details of the target house.

This paper introduces a new, tiny, super-smart "searchlight" developed by scientists. It's based on a unique antibody found in sharks. They call it a VNAR (Variable New Antigen Receptor).

Here is how they built it and what it does, broken down step-by-step:

1. The Problem: The "MET" Lock

In many cases of Non-Small Cell Lung Cancer (NSCLC), the cancer cells have a specific lock on their surface called MET.

• The Issue: This lock is broken or duplicated in cancer cells, causing them to grow out of control.
• The Challenge: Doctors need a way to find these specific locks to see where the cancer is (diagnosis) and then attack them (treatment). Current tools are often too big, too expensive, or not specific enough.

2. The Solution: The Shark's "Tiny Key"

Scientists went to a nurse shark (a type of shark that lives in shallow waters) and gave it a tiny dose of the human MET protein. The shark's immune system, which is very different from ours, created a unique defense weapon: a VNAR.

• The Analogy: Think of a standard human antibody as a large, bulky key that can only open flat, simple locks.
• The Shark VNAR: This is a tiny, flexible, super-sharp key. Because it is so small and has a weird shape (it has a long, spiky "finger" called a CDR3 loop), it can reach into deep, hidden crevices of the MET lock that human keys can't touch. It fits perfectly.

3. Building the Theranostic Tool (The "See and Treat" Device)

The scientists took this tiny shark key and attached it to a human "handle" (an Fc protein) to make it stable and long-lasting in the body. They created a two-in-one tool called vMET1-Fc.

• The "See" Part (Imaging): They attached a glowing radioactive tag (Zirconium-89) to the tool. When injected into mice with lung cancer, the tool acted like a glowing GPS tracker. It flew through the bloodstream, ignored all the healthy cells, and stuck tightly to the cancer cells. A PET scan could then light up exactly where the tumors were.
• The "Treat" Part (Therapy): They swapped the glowing tag for a radioactive "bomb" (Lutetium-177). This is a beta-particle emitter. When the tool found the cancer cell, it delivered a lethal dose of radiation directly to the tumor, killing it from the inside out while sparing the healthy neighbors.

4. How It Works in Action

• The Delivery: The tool is injected into the blood.
• The Search: It zooms through the body. Because it is small and smart, it clears out of the blood quickly (so it doesn't linger and hurt healthy organs).
• The Capture: It finds the MET locks on the cancer cells and grabs on tight.
• The Entry: Once attached, the cancer cell actually eats the tool (internalization), pulling it inside. This is great because it traps the radioactive "bomb" right inside the target.
• The Result: In the mouse experiments, the radioactive tool stopped the tumors from growing and significantly extended the lives of the mice.

5. Safety Checks (The "Primate Test")

Before this can be used in humans, it has to be safe. The scientists tested it on rhesus macaques (monkeys that are very similar to humans).

• The Result: The tool behaved perfectly. It cleared out of the body through the kidneys (like normal waste), didn't build up in the brain or heart, and caused no immune reactions or blood problems. It was safe.

Why This Matters

• Precision: It's like using a sniper rifle instead of a shotgun. It hits only the cancer.
• Versatility: Because it's a "theranostic," doctors can use the same tool to first scan a patient to see if they have the MET mutation, and if they do, they can immediately use the same tool to treat them.
• Shark Power: This proves that shark antibodies are a goldmine for medicine. They are smaller, cheaper to make, and can reach targets that human antibodies can't.

The Bottom Line

The researchers have created a shark-derived, two-in-one medical tool that can find lung cancer cells with a glowing light and then destroy them with a targeted radioactive dose. It works like a guided missile that only explodes when it hits the enemy, leaving the rest of the city (the body) unharmed. This is a major step forward in treating lung cancer that is resistant to current drugs.

Technical Summary

1. Problem Statement

Non-small cell lung cancer (NSCLC) is frequently driven by dysregulation of the MET receptor tyrosine kinase, occurring via amplification (6%), overexpression (80%), or mutation (specifically MET exon 14 skipping, ~3-4%). While tyrosine kinase inhibitors (TKIs) like capmatinib and tepotinib are effective, resistance inevitably develops. Antibody-based therapies are emerging alternatives, but conventional monoclonal antibodies (IgGs) face limitations:

• Structural Constraints: Large size and rigid complementarity-determining regions (CDRs) limit access to cryptic epitopes.
• Pharmacokinetics: Suboptimal tissue penetration and high manufacturing costs.
• Clinical Failures: Previous MET-directed antibodies (e.g., onartuzumab, emibetuzumab) have failed to improve survival in late-phase trials.
• Theranostic Gap: There is currently no described agent capable of both imaging (diagnostic) and treating (therapeutic) MET-altered NSCLC simultaneously.

2. Methodology

The study utilized a "shark-derived" approach to develop a novel targeting vector:

• Immunization & Discovery: A juvenile nurse shark (Ginglymostoma cirratum) was immunized with the extracellular domain of human MET. A phage display library was generated from the shark's immune repertoire.
• Screening & Engineering:
  • High-affinity binders were identified via ELISA and Next-Generation Sequencing (NGS).
  • The lead clone, vMET1, was engineered into a bivalent human IgG1 Fc fusion protein (vMET1-Fc) to enhance affinity and stability.
• In Vitro Characterization:
  • Binding Affinity: Measured via Biolayer Interferometry (BLI) against human, murine, and macaque MET.
  • Cellular Binding: Flow cytometry and Western blotting were used to correlate vMET1-Fc binding with MET expression levels (RNA, copy number, protein density) across various cell lines (EBC-1, UW-Lung-21, T-47D).
  • Functionality: Assessed for effects on cell viability, downstream signaling (p-MET), and HGF ligand competition.
  • Internalization: Monitored using pH-sensitive fluorophores (pHrodo) and confocal microscopy to track endolysosomal uptake.
• In Vivo Imaging & Therapy:
  • Imaging: vMET1-Fc was radiolabeled with Zirconium-89 ($^{89}$Zr) for PET/CT imaging in mouse xenograft models.
  • Therapy: vMET1-Fc was radiolabeled with Lutetium-177 ($^{177}$Lu) for targeted beta-particle radiotherapy.
  • Efficacy: Tumor growth delay and survival were monitored in MET-amplified (EBC-1) and METex14-mutated (UW-Lung-21) xenografts.
• Safety & Translational Studies:
  • Toxicity: Acute toxicity studies in immunocompetent mice (blood chemistry, histology).
  • Immunogenicity: Evaluated anti-drug antibody (ADA) responses in mice after repeated dosing.
  • Non-Human Primate (NHP) Study: Pharmacokinetics, biodistribution, and safety were assessed in healthy rhesus macaques using $^{89}$Zr-vMET1-Fc PET/CT and blood analysis.

3. Key Contributions

• First MET-Targeted VNAR: This is the first report of a shark-derived Variable New Antigen Receptor (VNAR) specifically targeting MET.
• Theranostic Platform: The study establishes a single molecular scaffold (vMET1-Fc) that can be radiolabeled with either diagnostic ($^{89}$Zr) or therapeutic ($^{177}$Lu) isotopes, enabling a "see and treat" strategy.
• Superior Affinity Engineering: The transition from a monomeric VNAR (KD ~34 nM) to a bivalent Fc-fusion (KD ~26 pM) resulted in picomolar affinity, overcoming the fast dissociation rates typical of single-domain antibodies.
• Epitope Accessibility: The VNAR's protruding CDR3 loop allows it to bind the MET SEMA domain with high specificity, a region often inaccessible to conventional antibodies.

4. Key Results

• Binding Specificity: vMET1-Fc showed high affinity for human and macaque MET but no cross-reactivity with murine MET (facilitating mouse safety studies). It bound specifically to MET-expressing cells with a strong correlation to MET receptor density ($R=0.82$).
• Mechanism of Action:
  • Non-Interfering: Unlike TKIs, vMET1-Fc did not inhibit MET signaling or cell proliferation, nor did it block HGF binding. This suggests a lower risk of driving resistance via signaling adaptation.
  • Internalization: The construct rapidly internalized into MET-positive cells (half-life ~22–35 hours), a critical feature for delivering cytotoxic payloads.
• Imaging Performance ($^{89}$Zr-vMET1-Fc):
  • PET/CT imaging in mice showed high tumor uptake and rapid blood clearance.
  • Tumor-to-heart ratios reached 4.0–4.6 at 96 hours in MET-positive models, compared to 2.8 in MET-negative controls.
  • Biodistribution confirmed high tumor accumulation (20–30% ID/g) with low background in normal tissues.
• Therapeutic Efficacy ($^{177}$Lu-vMET1-Fc):
  • Single-dose treatment significantly delayed tumor growth and improved progression-free survival.
  • Survival Benefit: Median survival increased 2-fold in EBC-1 models (47 vs. 19 days) and 3–4 fold in UW-Lung-21 models (37 vs. 9–13 days) compared to controls.
  • Estimated tumor dose delivery was ~18–20 Gy.
• Safety Profile:
  • Mice: No significant weight loss or organ toxicity (liver/kidney) was observed. Transient hematologic changes resolved within 30 days.
  • Immunogenicity: ADA responses in mice were comparable to a commercial humanized antibody (onartuzumab), suggesting low immunogenicity risk.
  • NHPs: Pharmacokinetics showed predictable clearance (renal/hepatic) with an in vivo half-life of ~40–45 hours. No significant off-target uptake or adverse blood chemistry changes were observed.

5. Significance

This work represents a milestone in the development of shark-derived VNARs as clinical theranostic agents.

• Overcoming Antibody Limitations: By utilizing a smaller, more flexible scaffold, vMET1-Fc accesses epitopes and achieves binding kinetics superior to traditional IgGs.
• Synergistic Radiotherapy: The study highlights a unique biological synergy where MET-targeted radiotherapy may enhance DNA damage repair inhibition, as MET signaling is linked to radiation resistance.
• Clinical Translation Potential: The favorable biodistribution, low toxicity, and predictable pharmacokinetics in non-human primates suggest vMET1-Fc is a strong candidate for clinical translation. It offers a solution for patients with MET-altered NSCLC who have developed resistance to TKIs or require a targeted approach with built-in patient selection (via PET imaging) and real-time dosimetry.
• Future Directions: The platform's versatility allows for the potential incorporation of alpha-emitters (e.g., Ac-225) or antibody-drug conjugates (ADCs), positioning it as a versatile next-generation therapeutic strategy.